Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differential Diagnosis of Tumor-like Brain Lesions.
Perez Giraldo GS, Singer L, Cao T, Jamshidi P, Dixit K, Kontzialis M, Castellani R, Pytel P, Anadani N, Bevan CJ, Grebenciucova E, Balabanov R, Cohen BA, Graham EL. Perez Giraldo GS, et al. Among authors: balabanov r. Neurol Clin Pract. 2023 Oct;13(5):e200182. doi: 10.1212/CPJ.0000000000200182. Epub 2023 Aug 30. Neurol Clin Pract. 2023. PMID: 37664132 Review.
Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity.
Perez Giraldo GS, Ali ST, Kang AK, Patel TR, Budhiraja S, Gaelen JI, Lank GK, Clark JR, Mukherjee S, Singer T, Venkatesh A, Orban ZS, Lim PH, Jimenez M, Miller J, Taylor C, Szymanski AL, Scarpelli J, Graham EL, Balabanov RD, Barcelo BE, Cahan JG, Ruckman K, Shepard AG, Slutzky MW, LaFaver K, Kumthekar PU, Shetty NK, Carroll KS, Ho SU, Lukas RV, Batra A, Liotta EM, Koralnik IJ. Perez Giraldo GS, et al. Among authors: balabanov rd. Ann Neurol. 2023 Jul;94(1):146-159. doi: 10.1002/ana.26649. Epub 2023 Apr 19. Ann Neurol. 2023. PMID: 36966460
Editorial: Cytokines and CNS diseases.
Balabanov R. Balabanov R. Front Cell Neurosci. 2023 Nov 27;17:1335455. doi: 10.3389/fncel.2023.1335455. eCollection 2023. Front Cell Neurosci. 2023. PMID: 38089144 Free PMC article. No abstract available.
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study.
Perumal J, Balabanov R, Su R, Chang R, Balcer LJ, Galetta SL, Avila RL, Rutledge D, Fox RJ. Perumal J, et al. Among authors: balabanov r. CNS Drugs. 2023 Mar;37(3):275-289. doi: 10.1007/s40263-022-00982-6. CNS Drugs. 2023. PMID: 36780107 Free PMC article.
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.
Perumal J, Balabanov R, Su R, Chang R, Balcer LJ, Galetta SL, Avila RL, Rutledge D, Fox RJ. Perumal J, et al. Among authors: balabanov r. CNS Drugs. 2022 Sep;36(9):977-993. doi: 10.1007/s40263-022-00950-0. Epub 2022 Sep 5. CNS Drugs. 2022. PMID: 36064841 Free PMC article.
Repurposing the cardiac glycoside digoxin to stimulate myelin regeneration in chemically-induced and immune-mediated mouse models of multiple sclerosis.
Titus HE, Xu H, Robinson AP, Patel PA, Chen Y, Fantini D, Eaton V, Karl M, Garrison ED, Rose IVL, Chiang MY, Podojil JR, Balabanov R, Liddelow SA, Miller RH, Popko B, Miller SD. Titus HE, et al. Among authors: balabanov r. Glia. 2022 Oct;70(10):1950-1970. doi: 10.1002/glia.24231. Epub 2022 Jul 9. Glia. 2022. PMID: 35809238 Free PMC article.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
63 results